<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463499</url>
  </required_header>
  <id_info>
    <org_study_id>2017-08-106</org_study_id>
    <nct_id>NCT03463499</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients</brief_title>
  <official_title>The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate after
      transurethral resection of Hunner lesion in interstitial cystitis/bladder pain syndrome
      patients. To analyze the number and timing of recurrence based on a long-term follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in recurrence rate in Hyaluronic Acid and Chondroitin Sulfate instillation group after transurethral resection treatment</measure>
    <time_frame>Every 3 months for 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in mean number of daytime frequency episodes</measure>
    <time_frame>Every 3 months for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in mean number of nocturia episodes</measure>
    <time_frame>Every 3 months for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in mean number of urgency episodes</measure>
    <time_frame>Every 3 months for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change score of O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q)</measure>
    <time_frame>Every 3 months for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change score of Pelvic Pain and Urgency/Frequency Patient Symptom Scale(PUF)</measure>
    <time_frame>Every 3 months for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of Global Response Assessment (GRA)</measure>
    <time_frame>Every 3 months for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment</measure>
    <time_frame>at the end of the treatment(2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse event</measure>
    <time_frame>Every 3 months for 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Interstitial Cystitis</condition>
  <arm_group>
    <arm_group_label>Hyaluronic Acid and Chondroitin Sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronic Acid and Chondroitin Sulfate</intervention_name>
    <description>Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.</description>
    <arm_group_label>Hyaluronic Acid and Chondroitin Sulfate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female aged 20 yrs or greater

          2. Patients diagnosed with Hunner lesion in IC(interstitial cystitis)/BPS(Bladder Pain
             Syndrome) and who is scheduled to undergo transurethral resection

          3. Symptom persisted more than 6 months

          4. Pain VAS â‰¥4

        Exclusion Criteria:

          1. History of augmentation cystoplasty or previous transurethral coagulation/resection
             due to IC/BPS

          2. Child-bearing potential, pregnant or nursing women.

          3. Hematuria exceeds 1+ in the urinary dipstick (dipstick) examination.

          4. Urinary tract infection during run-in periods.

          5. Genitourinary tuberculosis or bladder,urethral and prostate cancer

          6. Recurrent urinary tract infection

          7. History of hysterectomy,mid-urethral sling,pelvic organ prolapse repair,vaginal
             delivery or Cesarean section,prostate operation or treatment etc within 6months.

          8. Neurologic disease history of cerebral infarction,multiple sclerosis or parkinsonism
             etc.-

          9. Using a indwelling catheter or execution of intermittent self catheterization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sangok Park</last_name>
    <phone>82-2-6007-5419</phone>
    <email>missusu@naver.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyu-Sung Lee, MD, PhD</last_name>
      <phone>82-2-3410-3554</phone>
      <email>ksleedr@skku.edu</email>
    </contact>
    <investigator>
      <last_name>Kyu-Sung Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>KYU-SUNG LEE</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

